Lysine methyltransferase 2D deficiency drives complete response to pembrolizumab in PD-L1-High cholangiocarcinoma: a case report and review of literature
Our findings advocate for combinatorial biomarker strategies incorporating epigenetic markers (KMT2D status) with PD-L1 expression to optimize ICI patient selection, while highlighting the need for vigilant toxicity monitoring in this subset.
Authors
- Xiaofang Li (ORCID: https://orcid.org/0000-0002-4210-7952)
- Shuang Li (ORCID: https://orcid.org/0000-0002-9193-0320)
- Liao Wang (ORCID: https://orcid.org/0000-0001-7112-5386)
Institutions
- Shanxi Academy of Medical Sciences (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1616361
- Citations
- 1
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.81